



MelNet update

20 May 2021



Melanoma Summit

New Zealand 2021

In case you missed it: The 2021 New Zealand Melanoma Summit is waiting for you!

10 - 12 September 2021

**Sir Owen G Glenn Building, University of Auckland
Auckland**

Early bird registration is now open

Join us at the sixth New Zealand Melanoma Summit to:

- connect with over 200 health professionals passionate about reducing the incidence and impact of melanoma in New Zealand
- examine and discuss recent developments in melanoma management
- be part of the launch of the long-awaited Quality Statements for Melanoma Care in New Zealand (formerly Standards of Service Provision for Melanoma Patients in New Zealand)
- identify priorities for action for New Zealand.

Secure the early bird rate. [Register now.](#)

Call for abstracts

MelNet members are invited to [submit abstracts](#) on innovative initiatives, research projects and models of best practice for melanoma prevention, diagnosis, treatment or care in New Zealand.

Submissions close 30 June 2021.

Have you seen the speaker line up?

Check out the draft programme on the [2021 Summit website.](#)

Thank you to our generous sponsors



Sunscreen (Product Safety Standard) Bill

MelNet has made a written submission in support of the introduction of mandatory sunscreen standards.

MelNet has recommended that products claiming to offer sun protection be classified as therapeutic products under the Therapeutic Products Regulatory Regime, and that AS/NZ Sunscreen Products Standard (AS/NZS 2604) be used as the mechanism to approve sunscreen properties in each product.

It is our understanding that the Therapeutic Goods Act may not be in place for some time. MelNet has therefore expressed support of the Sunscreen (Product Safety Standard) Bill as an interim regulatory measure until sunscreen products can be regulated as therapeutic products under the Therapeutic Goods Act.

Written submissions can be made until 26 May 2021.

[More information](#)

In the media | Owner of sunscreen testing lab used by NZ companies admits fraud; call for mandatory standard of sunscreens

The owner of United States laboratory AMA Laboratories that tested sunscreen products sold in New Zealand has pleaded guilty to falsifying results. Consumer NZ Chief Executive Jon Duffy said several New Zealand-based manufacturers had used AMA Laboratories to justify SPF claims, and any manufacturer that relied on reports from AMA Laboratories should urgently retest its products.

[Read the story](#)

Recent release: Multidisciplinary management of Merkel cell carcinoma

In this podcast, a pathologist, surgical oncologist, radiation oncologist and medical oncologist discuss the treatment of patients with Merkel cell carcinoma.

[Listen on the Melanoma Education Portal](#) (free log in required; for clinicians only).

Upcoming opportunities and events

Queenstown Research Week
30 August – 2 September 2021
Rydges Hotel, Queenstown

[Registrations](#) for QMB, Medsci and six associated satellite meetings of Queenstown Research Week 2021 are now open.

[More information](#)

Other upcoming opportunities and events

June	July
<p>2021 ASCO Annual Meeting 4 – 8 June 2021 Online Further information</p>	<p>RCPA Pathology Update 2021 2 – 4 July 2021 Sydney, Australia Further information</p>
<p>Certificate of Dermoscopy - Online 4 June - 16 July 2021 Online Further information</p>	<p>11th European Post-Chicago Melanoma/Skin Cancer Meeting 8 – 9 July 2021 Virtual event Further information</p>
<p>Certificate of Fundamental Dermatoscopy - Online 7 June 2021 Online Further information</p>	
<p>Rotorua GP CME 2021 10 - 13 June 2021 Rotorua Further information</p>	
<p>2nd Australasian Ocular Melanoma Alliance (AOMA) Summit 18 - 19 June 2021 Virtual event Further information</p>	
<p>22nd World Dermatology Congress 21 – 22 June 2021 Webinar Further information</p>	
	<p>For more events see the MelNet events calendar</p>

Recent MelNet website postings

Below is a selection of recent news postings on the MelNet website. Please visit the [website](#) to view all the latest news items.

[Circulating tumor DNA reflects uveal melanoma responses to protein kinase C inhibition](#)

[Pembrolizumab shows no significant decrease in health-related quality-of-life for patients with resected, high-risk stage III melanoma](#)

[Pembrolizumab adjuvant therapy: significant and clinically meaningful improvement in distant metastasis-free survival at a 3-5-year median follow-up](#)

[Review of literature to classify and describe predictive biomarkers for checkpoint inhibition in melanoma](#)

[Limitations in the literature regarding Mohs surgery and staged excision for melanoma - a critical review](#)

[Caucasian patients with acral lentiginous melanoma \(ALM\) have no worse outcome than non-ALM patients](#)

[Diagnostic tools used for melanoma: A survey of Australian general practitioners and dermatologists](#)

[Regression a favorable prognostic factor for patients with stage 1 and 2 melanomas](#)

[Development and validation of a web-based patient decision aid for immunotherapy for patients with metastatic melanoma](#)



Support our work. Donate to MelNet



Join us on facebook